Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to mo… Read more
Biovie Inc (BIVI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.230x
Based on the latest financial reports, Biovie Inc (BIVI) has a cash flow conversion efficiency ratio of -0.230x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.44 Million) by net assets ($19.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biovie Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Biovie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biovie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biovie Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pelat Timah Nusantara Tbk
JK:NIKL
|
-0.036x |
|
Galileo Mining Ltd
AU:GAL
|
-0.002x |
|
Aztec Land Comb Cert
PINK:AZLCZ
|
N/A |
|
Ridgetech, Inc.
NASDAQ:RDGT
|
-0.336x |
|
SPINNOVA OYJ EO 1
F:9HP
|
N/A |
|
NORTHERN FREEGOLD
F:8N6
|
-0.179x |
|
Remsons Industries Limited
NSE:REMSONSIND
|
0.250x |
|
Apollomics Inc. Class A Ordinary Shares
NASDAQ:APLM
|
2.900x |
Annual Cash Flow Conversion Efficiency for Biovie Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Biovie Inc from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $19.01 Million | $-19.03 Million | -1.001x | +44.47% |
| 2024-06-30 | $15.51 Million | $-27.95 Million | -1.802x | +31.32% |
| 2023-06-30 | $15.34 Million | $-40.25 Million | -2.624x | +49.28% |
| 2022-06-30 | $3.67 Million | $-18.99 Million | -5.173x | -149.94% |
| 2021-06-30 | $5.05 Million | $-10.45 Million | -2.070x | -2832.88% |
| 2020-06-30 | $-21.50 Million | $-1.63 Million | 0.076x | +106.45% |
| 2019-06-30 | $2.13 Million | $-2.50 Million | -1.174x | +78.99% |
| 2018-06-30 | $111.20K | $-621.34K | -5.588x | -936.97% |
| 2017-06-30 | $1.16 Million | $-623.62K | -0.539x | -530.93% |
| 2016-06-30 | $1.92 Million | $-163.63K | -0.085x | -107.07% |
| 2015-06-30 | $-54.12K | $-65.38K | 1.208x | +219.80% |
| 2014-06-30 | $171.39K | $-172.83K | -1.008x | -4828.56% |
| 2013-06-30 | $490.70K | $-10.04K | -0.020x | -- |